[
    {
        "id": "osp-1444",
        "type": "article-journal",
        "title": "Anti-platelet and Anti-thrombotic Effects of a Poly-ingredient formulation: In vitro and in vivo experimental evidences",
        "author": [
            {
                "family": "GL",
                "given": "Viswanatha"
            },
            {
                "family": "Rafiq",
                "given": "Mohamed"
            },
            {
                "family": "S",
                "given": "Rajesh"
            },
            {
                "family": "KS",
                "given": "Sandeep Rao"
            },
            {
                "family": "Azeemuddin",
                "given": "Mohammed"
            },
            {
                "family": "SD",
                "given": "Anturlikar"
            },
            {
                "family": "P",
                "given": "Rangesh"
            },
            {
                "family": "PS",
                "given": "Patki"
            }
        ],
        "URL": "https://omanscience.com/en/articles/anti-platelet-and-anti-thrombotic-effects-of-a-poly-ingredient-formulation-in-vitro-and-in-vivo-experimental-evidences",
        "language": "en",
        "issued": {
            "date-parts": [
                [
                    2012
                ]
            ]
        },
        "container-title": "Oman Medical Journal",
        "DOI": "10.5001/omj.2012.127",
        "publisher": "Oman Medical Specialty Board",
        "ISSN": "1999-768X",
        "abstract": "Objective: The present study was conducted to evaluate the efficacy of Abana® (a poly-ingredient formulation with natural constituents) on in vitro platelet aggregation and occlusion-induced deep venous thrombosis in rats. Methods: Anti-platelet property of Abana® was evaluated using ADP (Adenosin 5′-diphosphate) and adrenaline-induced platelet aggregation models, and anti-thrombotic activity was evaluated against occlusion-induced deep venous thrombosis model in wistar rats. Results: Under the in vitro conditions, Abana® (250, 500 and 1000 µg/ml) alleviated ADP and adrenaline-induced platelet aggregation in a dose-dependent manner. Abana® (1000 µg/ml) inhibited ADP and adrenaline-induced platelet aggregation by as much as 50.69% and 64.83% respectively. Furthermore, 6 days pre-treatment with Abana® (250 and 500 mg/kg, p.o.) in an in vivo study showed significant and dose-dependent protection against occlusion-induced deep venous thrombosis in rats. Conclusion: These findings suggest that Abana®, a polyherbal formulation possesses anti-platelet and anti-thrombotic activities in the experimental models of in vitro platelet aggregation and in vivo deep venous thrombosis in rats."
    }
]